Metabolic Engineering of Saccharomyces cerevisiae for De Novo Production of Kaempferol.

J Agric Food Chem

School of Chemical and Biomedical Engineering, College of Engineering , Nanyang Technological University, 62 Nanyang Drive , Singapore 637459 , Singapore.

Published: May 2019

Kaempferol is a polyphenolic compound with various reported health benefits and thus harbors considerable potential for food-engineering applications. In this study, a high-yield kaempferol-producing cell factory was constructed by multiple strategies, including gene screening, elimination of the phenylethanol biosynthetic branch, optimizing the core flavonoid synthetic pathway, supplementation of precursor PEP/E4P, and mitochondrial engineering of F3H and FLS. A total of 86 mg/L of kaempferol was achieved in strain YL-4, to date the highest production titer in yeast. Furthermore, a coculture system and supplementation of surfactants were investigated, to relieve the metabolic burden as well as the low solubility/possible transport limitations of flavonoids, respectively. In the coculture system, the whole pathway was divided across two strains, resulting in 50% increased cell growth. Meanwhile, supplementation of Tween 80 in our engineered strains yielded 220 mg/L of naringenin and 200 mg/L of mixed flavonoids-among the highest production titer reported via de novo production in yeast.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jafc.9b01329DOI Listing

Publication Analysis

Top Keywords

novo production
8
highest production
8
production titer
8
coculture system
8
metabolic engineering
4
engineering saccharomyces
4
saccharomyces cerevisiae
4
cerevisiae novo
4
production
4
production kaempferol
4

Similar Publications

Novel De Novo Intronic Variant of SYNGAP1 Associated With the Neurodevelopmental Disorders.

Mol Genet Genomic Med

February 2025

Department of Chemistry and Molecular Biology, Gothenburg University, Gothenburg, Sweden.

Background: SYNGAP1 encodes a Ras/Rap GTPase-activating protein that is predominantly expressed in the brain with the functional roles in regulating synaptic plasticity, spine morphogenesis, and cognition function. Pathogenic variants in SYNGAP1 have been associated with a spectrum of neurodevelopmental disorders characterized by developmental delays, intellectual disabilities, epilepsy, hypotonia, and the features of autism spectrum disorder. The aim of this study was to identify a novel SYNGAP1 gene variant linked to neurodevelopmental disorders and to evaluate the pathogenicity of the detected variant.

View Article and Find Full Text PDF

An elevated level of saturated fatty acids (SFAs) can cause non-alcoholic fatty liver disease (NAFLD). While n-3 polyunsaturated fatty acids (PUFAs) were shown to improve NAFLD, the effects of n-6 PUFAs in the liver have not been fully elucidated. We examined the association between NAFLD and n-6 PUFAs, particularly dihomo-γ-linolenic acid (DGLA), in patients with type 2 diabetes.

View Article and Find Full Text PDF

IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment.

Clin Pharmacol Ther

January 2025

Clinical Pharmacology, Genentech/Roche, South San Francisco, California, USA.

An immunogenicity risk assessment (IRA) is a relatively new expectation of health authorities that is increasingly incorporated into the drug development process across the pharmaceutical/biotech industry. The guiding principle for an IRA includes a comprehensive evaluation of product- and patient-related factors that may influence the immunogenic potential of a biotherapeutic drug and a potential action plan. The Immunogenicity Working Group from the IQ Consortium (Clinical Pharmacology Leadership Group) has conducted a survey to understand the current practices for conducting IRAs and relevant aspects of bioanalysis.

View Article and Find Full Text PDF

Background: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder with dysregulated glyoxylate metabolism in the liver. Oxalate over-production leads to renal stones, progressive kidney damage and renal failure, with potentially life-threatening systemic oxalosis. Nedosiran is a synthetic RNA interference therapy, designed to reduce hepatic lactate dehydrogenase (LDH) to decrease oxalate burden in PH.

View Article and Find Full Text PDF

The upsurging of cost-effective electrocatalysts through the operando electro-oxidation approaches holds great promise for the scalable production of green energy in the pursuit of energy sustainability. This work introduces an operando electro-oxidation reconstitution strategy in producing a smart electrocatalyst, cobalt "oxyhydroxide" derived from a newly designed 2D cobalt(II) metal-organic framework (-) directly grown on nickel foam (NF), . The electrocatalyst, , exhibits an outstanding overpotential of 76 mV for the hydrogen evolution reaction and 336 mV for the oxygen evolution reaction to achieve a current density of 10 mA/cm with remarkable Faradaic efficiencies of 97.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!